An M&A deal is a transaction where two companies combine (a merger) or one company buys another (an acquisition). The term “M&A” covers a broad range of corporate transactions, from a small business buying a local competitor to a multibillion-dollar takeover of a publicly traded company. Though “merger” and “acquisition” technically describe different structures, the phrase “M&A deal” is used as a catch-all for any transaction that changes corporate ownership or control.
Mergers vs. Acquisitions
A merger happens when two separate companies agree to combine into a single new entity. Both companies surrender their existing stock, new shares are issued under the new business name, and a joint management structure takes shape with members from each firm. Neither company technically “buys” the other. Instead, each side dilutes its individual power to form something new.
An acquisition is more straightforward: one company purchases most or all of another company’s shares to gain control. The buyer (often called the acquirer) absorbs the target company. The target may continue operating under its own name, or it may be folded entirely into the buyer’s operations. A key distinction people in the industry draw is tone: friendly deals, where both boards agree, are often called mergers even if the structure is technically an acquisition. Hostile deals, where the target’s board resists, are almost always called acquisitions or takeovers.
How the Purchase Is Structured
Beyond the merger-versus-acquisition label, the structure of the deal itself determines what the buyer actually receives, what liabilities transfer, and how taxes work. The two most common structures are asset purchases and stock purchases.
Asset Purchases
In an asset purchase, the buyer picks specific assets it wants: equipment, intellectual property, customer contracts, real estate. The buyer can also choose which liabilities, if any, it will take on. This is a major advantage because it limits exposure to unknown debts or pending lawsuits the seller hasn’t disclosed. On the tax side, asset purchases let the buyer “step up” the tax basis of the acquired assets to their current fair market value. That means larger depreciation and amortization deductions going forward. Goodwill, the premium paid above the value of tangible assets, can be amortized over 15 years for tax purposes.
Stock Purchases
In a stock purchase, the buyer purchases the target company’s shares and takes the company as it finds it, assets and liabilities included. Everything transfers at its existing book value. The buyer doesn’t get the step-up tax benefit, and goodwill that exists as a share price premium isn’t tax-deductible. The only way to shed unwanted liabilities in a stock deal is to negotiate separate agreements where the seller agrees to take them back. Stock purchases are simpler to execute, though, because the company stays intact. Contracts, licenses, and permits typically don’t need to be individually reassigned.
How Buyers Pay
M&A deals can be paid for in three broad ways: cash, stock, or a combination of both. In an all-cash deal, the buyer pays a set price per share or a lump sum for the business. The seller walks away with a known amount. In a stock deal, the buyer issues new shares to the seller’s owners, making them partial owners of the combined company. Many large transactions blend both, offering some cash upfront and some equity in the surviving entity.
Where things get more creative is with earnouts. An earnout is a contingent payment tied to how the acquired business performs after the deal closes. If the company hits certain targets, the seller gets additional money. If it doesn’t, the buyer pays less. Earnouts are especially common in industries where a company’s future value is uncertain at the time of sale. In the pharmaceutical sector, over 80% of private transactions have included earnouts in recent years, largely because a drug’s commercial success often depends on clinical trials or regulatory approvals that haven’t happened yet.
Outside life sciences, earnout usage has fluctuated, rising from about 15% of deals in 2019 to a peak of 30 to 37% in 2023 before settling around 22% in 2024. The median earnout payment in non-life-sciences deals was about 31% of the closing payment in 2024, meaning a significant chunk of the total price was contingent on future performance.
Most earnouts are measured using financial metrics. Revenue is the most popular benchmark because it’s harder to manipulate through accounting changes. Buyers tend to prefer net income or EBITDA (earnings before interest, taxes, depreciation, and amortization), which reflects actual profitability rather than just top-line sales. Some deals use non-financial milestones like customer retention rates, commodity prices, or completion of a regulatory approval.
What Happens During the Deal Process
An M&A deal typically moves through several stages, and the timeline can range from a few weeks for a small private transaction to well over a year for a large public deal with regulatory hurdles.
It usually starts with one side identifying the opportunity. A buyer might approach a target directly, or an investment bank may run a formal auction process where multiple potential buyers submit bids. Early conversations involve signing a non-disclosure agreement so both sides can share sensitive financial information.
Next comes due diligence, the deep investigation phase. The buyer’s team examines the target’s financial statements, contracts, intellectual property, employee agreements, pending litigation, tax filings, and anything else that affects the company’s value or risk profile. Due diligence can take anywhere from a few weeks to several months depending on the complexity of the business.
Once both sides are satisfied, they negotiate the definitive agreement, the binding contract that spells out the purchase price, deal structure, representations and warranties (promises each side makes about the accuracy of what they’ve disclosed), and conditions that must be met before the deal can close. Those conditions often include shareholder approval, regulatory clearance, and the absence of any material changes to the business between signing and closing.
Regulatory Review and Approval
Deals above a certain size trigger mandatory government review. In the United States, the Hart-Scott-Rodino (HSR) Act requires parties to notify the Federal Trade Commission and the Department of Justice before closing. The agencies review whether the combined company would substantially reduce competition in any market. If regulators have concerns, they can request additional information, negotiate conditions (like requiring the buyer to sell off certain business units), or sue to block the deal entirely.
The regulatory environment has grown more complex. Updated HSR filing rules and merger guidelines have increased scrutiny on large transactions. Negotiations over regulatory risk allocation have intensified, with sellers pushing for higher “reverse termination fees,” payments the buyer owes if the deal falls apart because of a regulatory block. Deals are also being structured with longer outside dates, the contractual deadline by which a deal must close or either side can walk away, to account for extended review timelines.
Cross-border deals face additional layers. European and UK regulators conduct their own reviews, and they’ve shown less willingness to approve mergers where the combined company won’t maintain a strong local presence in terms of headquarters, leadership, or jobs. Any deal involving companies with significant international operations may need clearance from multiple countries simultaneously.
Why Companies Pursue M&A
Companies do deals for a variety of strategic reasons. The most common is growth: buying a competitor or a complementary business can be faster than building those capabilities internally. A technology company might acquire a startup for its product rather than spending years developing something similar. A retailer might buy a rival to gain access to new markets or a larger customer base.
Cost savings, often called synergies, are another major driver. When two companies combine, they can often eliminate duplicate functions like overlapping corporate offices, redundant manufacturing facilities, or parallel sales teams. These savings can be substantial, and buyers frequently cite projected synergies to justify the premium they’re paying.
Other motivations include acquiring talent (sometimes called an “acqui-hire”), gaining intellectual property or patents, diversifying into new industries, or simply deploying excess cash in a way that shareholders will find more productive than stock buybacks or dividends. In some cases, a company pursues an acquisition defensively, buying a potential disruptor before it becomes a serious competitive threat.
What It Means for Employees and Shareholders
If you work at a company being acquired, the practical impact depends on the deal’s structure and the buyer’s plans. Some acquisitions result in minimal day-to-day changes, especially when the buyer wants to preserve the target’s culture and operations. Others lead to significant restructuring, layoffs in overlapping departments, and changes to benefits, reporting lines, or office locations. Employment agreements and retention bonuses are sometimes negotiated as part of the deal for key employees the buyer wants to keep.
For shareholders of a publicly traded target, an acquisition typically means receiving a premium above the current stock price, often 20% to 40% or more. You’ll be offered cash, stock in the acquiring company, or a mix. In a merger of equals, you’ll receive shares in the new combined entity. The deal must usually be approved by a majority of shareholders, so you’ll get a vote and detailed disclosure documents explaining the terms before the transaction closes.